FDA Approves Xcopri (cenobamate) for the Treatment of Partial-Onset Seizures in Adults
FDA Approves Xcopri (cenobamate) for the Treatment of Partial-Onset Seizures in Adults Print this page PANGYO, South Korea and PARAMUS, N.J., Nov. 21, 2019 /PRNewswire/ — SK Biopharmaceuticals, Co., Ltd., an innovative global pharmaceutical company focused on developing and bringing treatments to market for central nervous system (CNS) disorders, and its U.S. subsidiary SK Life… Read More »